TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05244538

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality distraction
Description: Patients will be exposed to a virtual reality representing a forest walk. A reduction of at least 50 percent in the remifentanil and propofol doses required for oocyte retrieval is expected.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol-remifentanil sedation
Description: Target controlled infusion (TCI) of remifentanil will be started at an effect concentration (Ce) of 1.5 ng/mL and TCI propofol at Ce 1.5 ug/mL.~The concentration of remifentanil will be adjusted in 0.5 ng/ml increments based on hand sign from the patient with a maximum effect concentration of remifentanil at 2.5 ng/ml.
Study: NCT05320328

Intervention type: DEVICE
Intervention: Radio frequency ablation
Description: Radiofrequency ablation (RFA) uses heat to kill cancer cells. High-frequency electrical currents are passed through a special needle or probe called a needle electrode. The electrical current from the probe heats a small area containing cancer cells to high temperatures, killing the cancer cells. The area around the tumour is also usually treated because it may contain cancer cells.
Study: NCT04890106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test - Bimatoprost 0.01% Ophthalmic Solution
Description: Subjects in one arm will receive one drop of the test drug in both the eyes every evening at approximately 10:00 pm ± 2 hours for 42 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)
Description: Subjects in the second arm will receive one drop of the reference drug in both the eyes every evening at approximately 10:00 pm ± 2 hours for 42 days.
Study: NCT05841108

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: force feedback rehabilitation robot (SEM™ Glove)
Description: In the experimental group, the therapists were asked to illustrate and demonstrate the motor points of the cylindrical grasping and spherical grasping movements, and the patients were instructed to imitate them with nonparalytic hand, while the latter patients wore SEM™ Glove were used for task-oriented training, such as inserting pegs, grasping a ball into a barrel, and drinking water exercises. The difficulty of task-oriented training can be adjusted according to the patient's actual condition, such as changing the shape, weight, size of the target or changing the distance, duration, and so on during training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: assisted by a therapist
Description: The control group received task-oriented training assisted by a therapist to complete the same task as the experimental group. Therapists need to instruct patients to try to grasp items and give appropriate assistance to guarantee their completion of the grasping task. If finger extension is weak, the therapist assists the patient in extension of the digits before grasping the items, and if the finger flexion angle does not meet the grasp function needs, it should assist in flexion finger movements
Study: NCT04370730

Intervention type: OTHER
Group type: OTHER
Intervention: clinical, neuroimaging and DNA assessments
Description: Selected assessments, including evaluation of treatment response to specific antipsychotic drugs, will be performed at follow-up visits after 1, 3 and 5 years
Study: NCT06350812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB-119
Description: Administered subcutaneously once a week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously once a week
Study: NCT05801198

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Artemisia afra or Annua 10g oral infusion/tea per day for 14 days
Description: Participants will be recruited after completing standard malaria treatment, and those who have a positive qRT-PCR for plasmodium gametocyte reservoirs will be randomly assigned to either artemisia afra tea, or artemisia annua tea or into the control group with no intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Artemisia afra or Annua 10g oral infusion/tea per day for 14 days
Description: Participants will be recruited after completing standard malaria treatment, and those who have a positive qRT-PCR for plasmodium gametocyte reservoirs will be randomly assigned to either artemisia afra tea, or artemisia annua tea or into the control group with no intervention
Study: NCT06343272

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EAA supplementation
Description: The experimental group will receive the mixture (Amino-Ther® PRO, Professional Dietetics, Milan) composed of (in mg): L-leucine 1200, l L-isine 900, L-threonine 700, L-isoleucine 600, L-valine 600, L-cystine 150, L histidine 150, L-phenylalanine 100, L-methionine 50, L-tryptophan 50, vitamin B6 0.85, vitamin B1 0.70, citric acid 409, acidomalic 102.5, succinic acid 102.5.~1 sachet dissolved in 150 ml of water at 10.00 am +1 sachet at 4.00 pm daily for 60 days There are: proteins 0.00 g, carbohydrates 2.1 g, fats 0.00 g

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Isocaloric placebo
Description: The control group will take 25g of maltodextrins daily with the same methods as the treated group: 1 sachet dissolved in 150 ml of water at 10.00 am +1 sachet at 4.00 pm daily for 60 days
Study: NCT05459038

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: C-Arm Rotational View (CARV)
Description: CARV includes predefined fluoroscopy landmarks of the uninjured side to correct for rotational malalignment of the injured side in which the rotation of the C-Arm Image Intensifier is used
Study: NCT06394557

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: In-office Dental Bleaching Conventional
Description: Participants will undergo 2 sessions of in-office dental bleaching, using a 35% Hydrogen Peroxide bleaching gel, with 7 days of interval between sessions. Bleaching gel will be used in 3 15-minutes applications as indicated by the manufacturer. A 2% Potassium Nitrate and Sodium Fluoride desensitizing gel will be applied 15 minutes before the dental bleaching procedure, in both sessions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In-office Dental Bleaching Alternative
Description: Participants will undergo 2 sessions of in-office dental bleaching, using a 35% Hydrogen Peroxide bleaching gel, with 2 days of interval between sessions. Bleaching gel will be used in 3 15-minutes applications as indicated by the manufacturer. A 2% Potassium Nitrate and Sodium Fluoride desensitizing gel will be applied 15 minutes before the dental bleaching procedure, in both sessions.
Study: NCT06213610

Intervention type: DRUG
Group type: OTHER
Intervention: Perindopril tablet
Description: Perindopril is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 8 mg of perindopril tert-butylamine.

Intervention type: DRUG
Group type: OTHER
Intervention: Perindopril tablet
Description: Perindopril is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 8 mg of perindopril tert-butylamine.

Intervention type: DRUG
Group type: OTHER
Intervention: Prestarium® A tablet
Description: Prestarium® A is manufactured by Les Laboratoires Servier Industrie, France. Each tablet contains 10 mg of perindopril arginine.

Intervention type: DRUG
Group type: OTHER
Intervention: Prestarium® A tablet
Description: Prestarium® A is manufactured by Les Laboratoires Servier Industrie, France. Each tablet contains 10 mg of perindopril arginine.
Study: NCT06392750

Intervention type: BEHAVIORAL
Intervention: Collection of tumor tissue specimens
Description: Collection of tumor tissue specimens during surgery
Study: NCT05114148

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holmium-166 radioembolization
Description: Individualized 166Ho-RE will be performed via a catheter during angiography. Dosimetry-based treatment planning will be individualized based on Q-Suite™ software.
Study: NCT04800471

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smart insulin pens and CGM
Description: Participants in this group will be monitored by Smart Insulin pens and Continuous Glucose Monitoring Devices

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Point of Care Glucose Group
Description: Participants in this group will be monitored by POC glucose values.
Study: NCT04961086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: energy drink
Description: An easily available 250 ml branded energy drink will be randomized to the partcipants after informed consent. Before and thirty minutes after drinking the given energy drink the participant cognition, heart rate, blood pressure and blood glucose will be measured.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: energy drink
Description: An easily available 250 ml branded energy drink will be randomized to the partcipants after informed consent. Before and thirty minutes after drinking the given energy drink the participant cognition, heart rate, blood pressure and blood glucose will be measured.
Study: NCT05163067

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined aerobic exercise and cognitive training program
Description: Participants will take part in a combined aerobic exercise and cognitive training program. The program will include moderate cycling exercise and cognitive game resolving at the same time. The tasks will be instructed and supervised by a fitness expert and a trained clinical neuropsychologist.
Study: NCT06309927

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suction curettage
Description: Surgical evacuation of the uterine cavity with electrical vacuum suction curette
Study: NCT04972123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPC - Capsaicin, Phenylephrine, Caffeine
Description: CPC is a combination of Capsaicin, Phenylephrine and Caffeine

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tilt Table Test
Description: Participant will undergo tilt tablet testing using the Italian protocol (see reference section). The Italian protocol includes 20 minutes of passive tilt at 70 degrees (Passive Phase) followed by nitroglycerin (NTG) administration and tilt testing for another 15 minutes (NTG Phase).

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Tilt Table Test
Description: Participant will undergo tilt tablet testing using the Italian protocol (see reference section). The Italian protocol includes 20 minutes of passive tilt at 70 degrees (Passive Phase) followed by nitroglycerin (NTG) administration and tilt testing for another 15 minutes (NTG Phase).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for CPC
Study: NCT05912283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synthetic Nitrile Condoms (53mm)
Description: 53mm width synthetic nitrile condoms

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synthetic Nitrile Condoms (56mm)
Description: 56mm width synthetic nitrile condoms

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Latex Condom
Description: Commercial natural rubber latex condom
Study: NCT06073210

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Imagery plus therapeutic exercise
Description: Aerobic exercise (20 minutes) and strengthening exercise (15 minutes) to which will be added a motor imagery intervention (imagining movements without actually doing them).
Study: NCT05473455

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental: Follicular aspiration with addition of follicular flushing.
Description: Follicular flushing if necessary up to 5 times using a double lumen needle for oocyte recovery
Study: NCT05748301

Intervention type: OTHER
Intervention: AI Clinician
Description: N/A - Study is observational study testing the feasibility of running the AI Clinician in real time.

Intervention type: OTHER
Intervention: AI Clinician
Description: N/A - Study is observational study testing the feasibility of running the AI Clinician in real time.
Study: NCT05881681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App-Delivered Mindfulness Training (MT)
Description: Unwinding Anxiety is an app-delivered mindfulness training program which includes a progression through 30+ daily modules. Each module's training is delivered via short video tutorials and animations (\~10 min/day). Each training builds on the previous one; modules are 'locked' so that they can only be viewed at a pace of 1/day (previous modules can be reviewed at any time). A built-in self-assessment is taken after every seven modules to ensure key concepts are learned before moving on with automated suggestions on which modules to repeat based on the self-assessment results. User-initiated guided practices range from short exercises (30 seconds) to manage anxiety the moment it arises to formal guided meditations (up to 15 minutes), and can be accessed at any time
Study: NCT04963023

Intervention type: OTHER
Intervention: Physical examinations
Description: BPCO physical examinations

Intervention type: OTHER
Intervention: Physical examinations
Description: BPCO physical examinations

Intervention type: OTHER
Intervention: Physical examinations
Description: BPCO physical examinations

Intervention type: OTHER
Intervention: Physical examinations
Description: BPCO physical examinations

Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: blood test in order to study immunologic markers

Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: blood test in order to study immunologic markers

Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: blood test in order to study immunologic markers

Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: blood test in order to study immunologic markers
Study: NCT04836611

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 1 blood sample
Description: 2 groups of subjects (group 1 : with diagnosis of CHS - group 2 : no diagnosis of CHS) will have 2 blood and 1 urine samples + 1 questionnaire
Study: NCT05204095

Intervention type: DEVICE
Intervention: Portable slit-lamp photography
Description: The enrolled patients will undergo portable slit-lamp photography with and without mydriasis and receive traditional slit-lamp photography for comparison.

Intervention type: DEVICE
Intervention: Portable slit-lamp photography
Description: The enrolled patients will undergo portable slit-lamp photography with and without mydriasis and receive traditional slit-lamp photography for comparison.
Study: NCT06073210

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action observation plus therapeutic exercise
Description: Aerobic exercise (20 minutes) and strengthening exercise (15 minutes) to which will be added a action observation intervention (observing movements without actually doing them).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sham action observation plus therapeutic exercise
Description: Aerobic exercise (20 minutes) and strengthening exercise (15 minutes) to which will be added a sham action observation intervention (observing space planets).
Study: NCT06007547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poractant Alfa
Description: Poractant alfa (Curosurf) 200mg/kg administered under direct laryngoscopy using a surfactant instillation catheter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Poractant Alfa
Description: Poractant alfa (Curosurf) 200mg/kg administered under direct laryngoscopy using a surfactant instillation catheter
Study: NCT05279365

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfizer/BioNTech (BNT162b2)
Description: participants will receive a booster dose (1st booster or 2nd booster) of vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna
Description: participants will receive a booster dose (1st booster or 2nd booster) of vaccine
Study: NCT05215119

Intervention type: PROCEDURE
Intervention: natural cycle endometrial preparation
Description: Cycles will be monitored from either day-10 or-12, according to patient's menstrual cycle length, with serial analysis of blood serum LH and progesterone levels and assessment of dominant follicle growth. In a spontaneous cycle, ovulation will be determined by a LH surge (\>20 IU/L) and a corresponding rise in progesterone (\>0.8 ng/ml). In a triggered cycle, ovulation will be determined by the administration of an hCG trigger when the dominate follicle reached \>16 mm (and LH was \<20 IU/L).
Study: NCT06507813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADC189 tablets
Description: Patients weigh between 20 to 80 kilograms, given 45 mg ADC189 tablets once; patients weigh over 80 kilograms, given 90 mg ADC189 tablets once.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baloxavir Marboxil tablets
Description: Patients weigh between 20 to 80 kilograms, given 40 mg Baloxavir marboxil tablets once. Patients weigh over 80 kilograms, given 80 mg Baloxavir marboxil tablets once.
Study: NCT05846867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK119
Description: AK119 IV every 2 weeks.intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK119
Description: AK119 IV every 2 weeks.intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK119
Description: AK119 IV every 2 weeks.intravenous infusion
Study: NCT05784818

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Up To Me Intervention + No Booster
Description: Participants will complete two-hour sessions once a week over three weeks in which they complete modules in the Up To Me Workbook. These sessions are facilitated by a peer facilitator and a member of the USF Counseling center. Other members in the group sessions are university students who are peers who are also experiencing some form of shame around their mental health challenges.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Up To Me Intervention + Booster
Description: In addition to the Up To Me Intervention, participants also complete a booster/additional session where additional topics of the Up To Me workbook are covered. This additional session occurs four weeks after the completion of the third session.
Study: NCT06507813

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baloxavir Marboxil tablets
Description: Patients weigh between 20 to 80 kilograms, given 40 mg Baloxavir marboxil tablets once. Patients weigh over 80 kilograms, given 80 mg Baloxavir marboxil tablets once.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of ADC189 tablets
Description: Patients weigh between 20 to 80 kilograms, given 1 tablet of placebo once; patients weigh over 80 kilograms, given 2 tablets of placebo once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Baloxavir Marboxil tablets
Description: Patients weigh between 20 to 80 kilograms, given 2 tablets of placebo once; patients weigh over 80 kilograms, given 4 tablets of placebo once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Baloxavir Marboxil tablets
Description: Patients weigh between 20 to 80 kilograms, given 2 tablets of placebo once; patients weigh over 80 kilograms, given 4 tablets of placebo once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADC189 granules
Description: For patient 5-11 years old, patients weigh between 20 to 80 kilograms, given 45 mg ADC189 granules once; patients weigh over 80 kilograms, given 90 mg ADC189 granules once.~For patient 2-4 years old, patients \<10kg, given 15mg ADC189 granules once. 10kg \~ \<15kg, given 25mg ADC189 granules once. 15kg \~\<20 kg, given 35mg ADC189 granules once. 20kg \~ \<80kg, given 45mg ADC189 granules once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADC189 granules
Description: For patient 5-11 years old, patients weigh between 20 to 80 kilograms, given 45 mg ADC189 granules once; patients weigh over 80 kilograms, given 90 mg ADC189 granules once.~For patient 2-4 years old, patients \<10kg, given 15mg ADC189 granules once. 10kg \~ \<15kg, given 25mg ADC189 granules once. 15kg \~\<20 kg, given 35mg ADC189 granules once. 20kg \~ \<80kg, given 45mg ADC189 granules once.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of ADC189 granules
Description: Placebo. Given once only.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of ADC189 granules
Description: Placebo. Given once only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Oseltamivir granules
Description: For patients 2-4 years old. Placebo. Given 10 times (5 days, BID).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir granules
Description: For patients 2-4 years old. Patients \<15kg, given 30mg×10 times (5 days, BID) Oseltamivir granules. 15kg \~ \<23kg, given 45mg×10 times (5 days, BID) Oseltamivir granules. 23kg \~ \<40kg, given 60mg×10 times (5 days, BID) Oseltamivir granules. ≥40kg, given 75mg×10 times (5 days, BID) Oseltamivir granules.
Study: NCT06284291

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation (TMS)
Description: The STM9000 Standard-BI stimulator with 70 mm refrigerated butterfly stimulator (EB Neuro, Florence, Italy) controlled by Galileo Netbrain 9000 hardware and software (EB Neuro, Florence, Italy) is used. EMG data are recorded from the contralateral dorsal first interosseous muscle using gelled surface electrodes. EEG data are recorded by using the BE PLUS PRO Advanced EEG/EMG/EP amplifier (EB Neuro, Florence, Italy IT).
Study: NCT05773495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: I-SITE Intervention
Description: I-SITE is a coaching facilitated implementation program that guides clinical personnel through tailored integration of teleophthalmology into primary care workflows.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care Teleophthalmology
Description: All sites will initially receive usual care teleophthalmology, consisting of having an active teleophthalmology program located in the primary care clinic and access to the I-SITE online toolkit. All sites will utilize non-mydriatic retinal cameras (e.g. Topcon NW400) located in their primary care clinic to obtain a single 45-degree photo of the disc and macula with an anterior photo in each eye to provide diabetic eye screening as part of patients' usual care. Images are captured by trained primary care personnel and securely transmitted to eye doctors for evaluation.
Study: NCT05035459

Intervention type: DIAGNOSTIC_TEST
Intervention: lung ultrasound
Description: drug adjustment based on lung ultrasound results

Intervention type: DIAGNOSTIC_TEST
Intervention: lung ultrasound
Description: drug adjustment based on lung ultrasound results

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung ultrasound
Description: drug adjustment independent on lung ultrasound results

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung ultrasound
Description: drug adjustment independent on lung ultrasound results
Study: NCT04872569

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision-making tool
Description: Participants will be directed to use the decision tool for 3 months using it at their own pace.~The tool covers topics relevant to women with disabilities in considering or planning a pregnancy and reflects core elements of decision making tools based on the Ottawa Framework for Decision Support.